{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-012538","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.784964+00:00","generated_at":"2026-06-17T01:18:00.605057+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INVO Bioscience reports 2022 revenue $0.8M, cash $0.1M; EBITDA loss widens to $(8.4)M","bullets":["FY 2022 revenue $822K (up 40% excl. Ferring license); Q4 revenue $278K, up 18% sequentially.","Adjusted EBITDA loss of $(8.4)M vs $(2.8)M in 2021; includes $0.3M acquisition costs and IP write-down.","Cash $0.1M at Dec 31, 2022; $3.0M gross raised in March 2023 registered direct offering.","Signed binding agreement to acquire Wisconsin Fertility Institute for $10M payable over 3 years; expected close Q2 2023.","Clinic revenue from all centers up 726% to $1.6M; Atlanta center contributed $614K."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-012538","json":"https://secwatch.observer/filing/0001493152-23-012538.json","markdown":"https://secwatch.observer/filing/0001493152-23-012538.md","text":"https://secwatch.observer/filing/0001493152-23-012538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:18:00.605057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3af259c2bb1c9fb67781c0618dd116d8eefe4f8","claim":"INVO Fertility, Inc. reported fourth quarter ended December 31, 2022 results: revenue $278,142.","evidence_excerpt":"Q4 2022 Financial Highlights (all metrics compared to Q4 2021 unless otherwise noted) ● Revenue was $278,142, compared to $12,532 (excluding license revenue), and was up 18% sequentially compared to the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$278,142"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fee771434abc7e5e73708701e5d316717e6260cd","claim":"INVO Fertility, Inc. reported year ended December 31, 2022 results: revenue $822,196.","evidence_excerpt":"2022 Financial Highlights (all metrics compared to 2021 unless otherwise noted) ● Revenue increased 40% to $822,196 compared to $588,687 (excluding license revenue) in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Revenue","value":"$822,196"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}